Meta-analysis: Rectal indomethacin for the prevention of post-ERCP pancreatitis

Alimentary Pharmacology and Therapeutics

Volumn 38, Issue 9, 2013, Pages 995-1001

  Yaghoobi, M ^a,b,c   Rolland, S ^d   Waschke, K A ^a   McNabb Baltar, J ^a,e   Martel, M ^a   Bijarchi, R ^a   Szego, P ^a   Barkun, A N ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d UNIVERSITÉ LAVAL   (Canada)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDOMETACIN; PLACEBO;

ARTICLE; DISEASE SEVERITY; DRUG DOSE COMPARISON; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; HIGH RISK PATIENT; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PANCREATITIS; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SENSITIVITY ANALYSIS; STUDY DESIGN; SYSTEMATIC REVIEW;

ADMINISTRATION, RECTAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; HUMANS; INDOMETHACIN; PANCREATITIS; RISK;

EID: 84885091584     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12488     Document Type: Article

References (28)

1. Freeman ML, Guda NM,. Prevention of post-ERCP pancreatitis: a comprehensive review. Gastrointest Endosc 2004; 59: 845-64. (Pubitemid 38879313)
2. Rabenstein T, Hahn EG,. Post-ERCP pancreatitis: new momentum. Endoscopy 2002; 34: 325-9. (Pubitemid 34279524)
3. Vandervoort J, Soetikno RM, Tham TC, et al,. Risk factors for complications after performance of ERCP. Gastrointest Endosc 2002; 56: 652-6. (Pubitemid 36531698)
4. Cavallini G, Tittobello A, Frulloni L, et al,. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy-Italian Group. N Engl J Med 1996; 335: 919-23. (Pubitemid 26314444)
5. Arvanatidis D, Anagnostopoulos GK, Giannopoulos D, et al,. Can somatostatin prevent post-ERCP pancreatitis? Results of a randomized controlled trial. J Gastroeneterol Hepatol 2004; 19: 278-82. (Pubitemid 38338736)
6. Gross V, Leser HG, Heinisch A, et al,. Inflammatory mediators and cytokines-new aspects of the pathophysiology and assessment of severity of acute pancreatitis? Hepatogastroenterology 1993; 40: 522-30. (Pubitemid 24006279)
7. Makela A, Kuusi T, Schroder T,. Inhibition of serum phospholipase-A2 in acute pancreatitis by pharmacological agents in vitro. Scand J Clin Lab Invest 1997; 57: 401-7. (Pubitemid 27344912)
8. Dai HF, Wang XW, Zhao K,. Role of nonsteroidal anti-inflammatory drugs in the prevention of post-ERCP pancre-atitis: a meta-analysis. Hepatobiliary Pancreat Dis Int 2009; 8: 11-6.
9. Döbrönte Z, Toldy E, Márk L, et al,. Effects of rectal indomethacin in the prevention of post-ERCP acute pancreatitis. Orv Hetil 2012; 153: 990-6.
10. Elmunzer BJ, Scheiman JM, Lehman GA, et al,. A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis. N Engl J Med 2012; 366: 1414-22.
11. Elmunzer BJ, Waljee AK, Elta GH, et al,. A meta-analysis of rectal NSAIDs in the prevention of post-ERCP pancreatitis. Gut 2008; 57: 1262-7.
12. Ding X, Chen M, Huang S, et al,. Nonsteroidal anti-inflammatory drugs for prevention of post-ERCP pancreatitis: a meta-analysis. Gastrointest Endosc 2012; 76: 1152-9.
13. Viera AJ, Garrett JM,. Understanding interobserver agreement: the kappa statistic. Fam Med 2005; 37: 360-3. (Pubitemid 40656185)
14. Higgins JP, Altman DG,. Assessing risk of bias in included studies. In:, Higgins J, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Chichester, UK: John Wiley & Sons, 2008; 187-206.
15. DerSimonian R, Laird N,. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88. (Pubitemid 17189972)
16. Begg CB, Mazumdar M,. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-101.
17. Egger M, Davey Smith G, Schneider M, Minder C,. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34. (Pubitemid 27387172)
18. Alderson P, Green S,. Cochrane Collaboration open learning material for reviewers. Version 1.1, Nov 2002, The Cochrane Collaboration®.
19. Liberati A, Altman DG, Tetzlaff J, et al,. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009; 151: W65-94.
20. Sotoudehmanesh R, Khatibian M, Kolahdoozan S, et al,. Indomethacin may reduce the incidence and severity of acute pancreatitis after ERCP. Am J Gastroenterol 2007; 102: 978-83. (Pubitemid 46698240)
21. Montaño Loza A, Rodríguez Lomelí X, García Correa JE, et al,. Effect of the administration of rectal indomethacin on amylase serum levels after endoscopic retrograde cholangiopancreatography, and its impact on the development of secondary pancreatitis episodes. Rev Esp Enferm Dig 2007; 99: 330-6.
22. Choudhary A, Bechtold ML, Arif M, et al,. Pancreatic stents for prophylaxis against post-ERCP pancreatitis: a meta-analysis and systematic review. Gastrointest Endosc 2011; 73: 275-82.
23. Dumonceau JM, Rigaux J, Kahaleh M, et al,. Prophylaxis of post-ERCP pancreatitis: a practice survey. Gastro-intest Endosc 2010; 71: 934-9, 931-9.
24. Andriulli A, Forlano R, Napolitano G, et al,. Pancreatic duct stents in the prophylaxis of pancreatic damage after endoscopic retrograde cholangiopancreatography: a systematic analysis of benefits and associated risks. Digestion 2007; 75: 156-63. (Pubitemid 47343973)
25. Das A, Singh P, Sivak MJ, et al,. Pancreatic-stent placement for prevention of post-ERCP pancreatitis: a cost-effectiveness analysis. Gastrointest Endosc 2007; 65: 960-8. (Pubitemid 46783815)
26. Elmunzer BJ, Higgins PD, Saini SD, et al,. Does rectal indomethacin eliminate the need for prophylactic pancreatic stent placement in patients undergoing high-risk ERCP? Post hoc efficacy and cost-benefit analyses using prospective clinical trial data. Am J Gastroenterol 2013; 108: 410-5.
27. Akbar A, Abu Dayyeh BK, Baron TH, et al,. Rectal nonsteroidal anti-inflammatory drugs are superior to pancreatic duct stents in preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a network meta-analysis. Clin Gastroenterol Hepatol 2013; 11: 778-83.
28. Van Der Marel C, Anderson B, Romsing J, et al,. Diclofenac and metabolite pharmacokinetics in children. Paediatr Anaesth 2004; 14: 443-51. (Pubitemid 38758661)